ReVance Therapeutics Receives $45,000,000 Series E Financing

  • Feed Type
  • Date
    6/10/2011
  • Company Name
    ReVance Therapeutics
  • Mailing Address
    7555 Gateway Boulevard Newark, CA 94560
  • Company Description
    Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin. The technology is being designed and tested to eliminate the need for needle injections, while permitting a safe, local, targeted, and painless approach to treat facial aesthetics and hyperhidrosis.
  • Website
    http://www.revance.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $45,000,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    The will continue to develop its topical and injectable neuromodulation pipeline in both aesthetic and therapeutic categories.
  • M&A Terms
  • Venture Investor
    Essex Woodlands Health Ventures
  • Venture Investor
    Essex Woodlands Health Ventures
  • Venture Investor
    Vivo Ventures
  • Venture Investor
    Technology Partners
  • Venture Investor
    NovaQuest
  • Venture Investor
    Shepherd Ventures
  • Venture Investor
    Palo Alto Investors
  • Venture Investor
    Pac-Link Bio

By posting a comment, you agree to our terms and conditions.